Compare Boston Scientific Corporation (BSX) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs J B Hunt Transport Services Inc — how do they compare? Boston Scientific Corporation trades at $51.47 (market cap $74.19B), while J B Hunt Transport Services Inc trades at $275.82 (market cap $24.92B). The key difference: Boston Scientific Corporation is far larger — about 3× J B Hunt Transport Services Inc's market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | JBHT | |
|---|---|---|
Market Cap | $74.19B | $24.92B |
Sector | Health | Industrials |
52-Week High | $108.14 | $298.41 |
52-Week Low | $42.63 | $130.65 |
Enterprise Value | $86.27B | $26.06B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
JBHT trades at $275.5, up 3.52% today, with a bearish technical signal but strong analyst consensus. The company reported revenue of $12.0B in 2025, with net income of $598.28M and a 5.31% net margin. Recent earnings have consistently beaten estimates, and the company announced a $0.45 dividend payable in August 2026. Cash flow from operations remains robust at $1.68B in 2025, though net cash flow was slightly negative.
The outlook is positive with a consensus price target of $299.82, implying 8.8% upside. Risks include competitive pressures and macroeconomic volatility, but strong institutional ownership and a buy rating from 57.8% of analysts support a favorable view. The stock's valuation multiples are elevated, but earnings growth and intermodal demand recovery provide catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
